Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWCAR029 in Primary Refractory DLBCL
NCT04812691Phase 1Completed
- Sponsor
- Shanghai Ming Ju Biotechnology
- Start
- Jul 2020
- Primary completion
- Jun 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of relmacabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Ming Ju Biotechnology. Primary endpoint: Types, frequency, and severity of adverse events and laboratory anomalies at 2 years. Started Jul 2020; status: completed.
02
Drugs
relmacabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04812691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812691.